Serina Therapeutics secures $10M equity financing from Juvenescence at $10/share (120% premium)

Serina Therapeutics, Inc.

Financing of 1M shares at $10/share, a 120% premium to Nov 26 closing price.
First $5M tranche received Nov 27, 2024; second $5M due by Jan 31, 2025.
Proceeds to advance SER-252 (POZ-apomorphine) into Phase 1 trial in advanced Parkinson's in H2 2025.
Juvenescence surrendered 755,728 post-merger warrants; received replacement incentive warrants exercisable at $18.
Special committee of independent directors approved the related-party transaction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.